4//SEC Filing
Margolis Jeff Eliot 4
Accession 0001493152-20-018818
CIK 0000849636other
Filed
Oct 1, 8:00 PM ET
Accepted
Oct 2, 3:47 PM ET
Size
36.6 KB
Accession
0001493152-20-018818
Insider Transaction Report
Form 4
Margolis Jeff Eliot
DirectorVice President, Sec. & Treas.Other
Transactions
- Gift
Series H Preferred Stock
2020-09-30+136→ 587.975 total(indirect: By Trust)Exercise: $0.01From: 2020-09-30Exp: 2023-09-30→ Conversion Units (21,250,000 underlying) - Gift
Series H Preferred Stock
2020-09-30+7→ 32.11 total(indirect: By Trust)Exercise: $0.01From: 2020-09-30Exp: 2023-09-30→ Conversion Units (1,093,750 underlying) - Conversion
Warrants (to purchase Common Stock)
2020-09-30+5,017,144→ 5,017,144 total(indirect: By Trust)Exercise: $0.01From: 2020-09-30Exp: 2023-09-30→ Common Stock (5,017,144 underlying) - Conversion
Common Stock
2020-09-30+5,017,144→ 5,142,351 total(indirect: By Trust) - Conversion
Common Stock
2020-09-30+5,017,144→ 5,142,351 total(indirect: By Trust) - Gift
Series H Preferred Stock
2020-09-30−136→ 14 totalExercise: $0.01From: 2020-09-30Exp: 2023-09-30→ Conversion Units (21,250,000 underlying) - Gift
Series H Preferred Stock
2020-09-30−7→ 7 totalExercise: $0.01From: 2020-09-30Exp: 2023-09-30→ Conversion Units (1,093,750 underlying) - Gift
Series H Preferred Stock
2020-09-30−7→ 0 totalExercise: $0.01From: 2020-09-30Exp: 2023-09-30→ Conversion Units (1,093,750 underlying) - Gift
Series H Preferred Stock
2020-09-30+7→ 32.11 total(indirect: By Trust)Exercise: $0.01From: 2020-09-30Exp: 2023-09-30→ Conversion Units (1,093,750 underlying) - Conversion
Common Stock
2020-09-30+91,871,094→ 96,151,863 total(indirect: By Trust) - Other
Series H Preferred Stock
2020-09-30+150→ 150 totalExercise: $0.01From: 2020-09-30Exp: 2023-09-30→ Conversion Units (23,437,500 underlying) - Conversion
Warrants (to purchase Common Stock)
2020-09-30+91,871,094→ 91,871,094 total(indirect: By Trust)Exercise: $0.01From: 2020-09-30Exp: 2023-09-30→ Common Stock (91,871,094 underlying) - Conversion
Warrants (to purchase Common Stock)
2020-09-30+5,017,144→ 5,017,144 total(indirect: By Trust)Exercise: $0.01From: 2020-09-30Exp: 2023-09-30→ Common Stock (5,017,144 underlying)
Footnotes (14)
- [F1]On September 30, 2020, each of the trusts into which Mr. Margolis transferred shares of the Company's Series H 2% Voting, Non-Participating, Convertible Preferred Stock ("Series H Preferred") converted all of their outstanding shares of the Series H Preferred into a total of 101,905,382 Conversion Units comprising 101,905,382 shares of the common stock of the Company and 101,905,382 warrants exercisable into 101,905,382 shares of the common stock of the Company.
- [F10]Mr. Margolis gifted these securities into a family trust for the benefit of Mr. Margolis's spouse. Mr. Margolis's spouse is a trustee of the trust. Mr. Margolis disclaims beneficial ownership of these securities, and the filing of this report is not an admission that Mr. Margolis is the beneficial owner of these securities for purposes of Section 16 or any other purpose.
- [F11]This reflects the 7 Series H Preferred shares transferred on September 30, 2020, plus 25 Series H Preferred shares previously transferred to the trust on July 13, 2020, plus 0.1097222 additional dividend shares of Series H Preferred on the 25 Series H Preferred shares held since July 13, 2020.
- [F12]Mr. Margolis gifted these securities into a family trust for the benefit of his son. Mr. Margolis's spouse is a trustee of the trust. Mr. Margolis disclaims beneficial ownership of these securities, and the filing of this report is not an admission that Mr. Margolis is the beneficial owner of these securities for purposes of Section 16 or any other purpose.
- [F13]This reflects the 7 Series H Preferred shares transferred on September 30, 2020, plus 25 Series H Preferred shares previously transferred to the trust on July 13, 2020, plus 0.1097222 additional dividend shares of Series H Preferred on the 25 Series H Preferred shares held since July 13, 2020.
- [F14]Mr. Margolis gifted these securities into a family trust for the benefit of his daughter. Mr. Margolis's spouse is a trustee of the trust. Mr. Margolis disclaims beneficial ownership of these securities, and the filing of this report is not an admission that Mr. Margolis is the beneficial owner of these securities for purposes of Section 16 or any other purpose.
- [F2]These securities are held by a family trust for the benefit of Mr. Margolis's spouse. Mr. Margolis's spouse is a trustee of the trust. Mr. Margolis disclaims beneficial ownership of these securities, and the filing of this report is not an admission that Mr. Margolis is the beneficial owner of these securities for purposes of Section 16 or any other purpose.
- [F3]These securities are held by a family trust for the benefit of Mr. Margolis's son. Mr. Margolis's spouse is a trustee of the trust. Mr. Margolis disclaims beneficial ownership of these securities, and the filing of this report is not an admission that Mr. Margolis is the beneficial owner of these securities for purposes of Section 16 or any other purpose.
- [F4]These securities are held by a family trust for the benefit of Mr. Margolis's daughter. Mr. Margolis's spouse is a trustee of the trust. Mr. Margolis disclaims beneficial ownership of these securities, and the filing of this report is not an admission that Mr. Margolis is the beneficial owner of these securities for purposes of Section 16 or any other purpose.
- [F5]The full designation of this class of preferred stock is "Series H 2% Voting, Non-Participating, Convertible Preferred Stock".
- [F6]On September 30, 2020, Mr. Margolis agreed to forgive a portion of accrued compensation owing from RespireRx Pharmaceuticals Inc. (the "Company") equal to $150,000, and in exchange, the Company issued to Mr. Margolis 150 shares of Series H Preferred stock, which equates to a per share value of $1,000.00 per share.
- [F7]Each Conversion Unit consists of one share of the common stock of the Company, and one warrant exercisable into one share of the common stock of the Company (such warrant having an initial exercise price of $0.007 per share, and terminating on September 30, 2023).
- [F8]These dispositions and acquisitions reflect estate planning transactions. These securities are being contributed to trusts for the benefit of Mr. Margolis' spouse and children, as specified.
- [F9]This reflects the 136 Series H Preferred shares transferred on September 30, 2020, plus 450 Series H Preferred shares previously transferred to the trust on July 13, 2020, plus 1.975 additional dividend shares of Series H Preferred on the 450 Series H Preferred shares held since July 13, 2020.
Documents
Issuer
RespireRx Pharmaceuticals Inc.
CIK 0000849636
Entity typeother
Related Parties
1- filerCIK 0001573202
Filing Metadata
- Form type
- 4
- Filed
- Oct 1, 8:00 PM ET
- Accepted
- Oct 2, 3:47 PM ET
- Size
- 36.6 KB